In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks ...

In fact, this is a broader industry trend, not only across healthcare, but other verticals ... the system to produce insights that align with healthcare’s strict standards. GSK’s second ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other cheapest stocks with biggest upside potential. Stocks rallied on January 15, following an encouraging ...

The US Food and Drug Administration recently gave IDRX-42 fast-track designation for treating patients with GIST who had shown resistance to other drugs ... approved products.' GSK shares were ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

as well as other ranitidine products sold by other companies – increased the risk of cancer. GSK has steadfastly denied that Zantac causes cancer, pointing to the lack of any reliable evidence ...

The three-day hearing comes a few months after GSK decided to settle a complaint ... called N-nitrosodimethylamine (NDMA) – as well as other ranitidine products – increased the risk of cancer.

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...